Physician
Oncology
Dr. Carmen J. Allegra, MD
|
|
Give Review
Carmen Allegra is an expert in the field of Oncology. He attended Perelman School of Medicine at the University of Pennsylvania. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Elected Member". Carmen Allegra has written publications. He has 32 publications published with PubMed. The lastest publication is: 'Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the...' Dr. Carmen J. Allegra accepts Medicare payments and is listed with Medicare.gov.
Publications
- Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the...
- Extended RAS Gene Mutation Testing in Metastatic ColoRectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: America...
- Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
- ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer.
- Continuous Publication of JNCI.
- Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08.
- Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial.
- The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report.
- The journal of the national Cancer institute: * the next generation.
- Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant ...
- Combination Therapy for Renal Cell Cancer: What Are Possible Options?
- Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time...
- Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses.
- Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
- National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.
- Preoperative multimodality therapy improves Disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
- NIH state-of-the-science conference statement: diagnosis and management of Ductal carcinoma in situ (DCIS).
- Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II ...
- American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic coloRectal carcinoma to predict respons...
- The marriage of growth factor inhibitors and chemotherapy: bliss or bust?
- Don Quixote and the quest for personalized medicine.
- Thymidylate synthase expression in colon carcinomas with microsatellite instability.
- Prevalence of burnout in the u.s. Oncology community: results of a 2003 survey.
- Cytotoxins and Cancer immunotherapy: the dance of the macabre?
- Microsatellite instability in colon Cancer.
- Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
- Thymidylate synthase protein expression in primary colorectal Cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
- Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon Cancer: a National Cancer Institute-National Surgical Adjuvant Breast an...
- The identification of thymidylate synthase peptide domains located in the interface region that bind thymidylate synthase mRNA.
- Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon Cancer.
Schools
University Of Pennsylvania School Of Medicine
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Elected Member
Education
-
National Institutes of Health Clinical Center -
University of Pennsylvania Health System -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
UF Health Shands Hospital
Drug Facts
| NPI NUMBER | 1063473890 | |
| NPPES Provider LastName | ALLEGRA | |
| NPPES Provider FirstName | CARMEN | |
| NPPES Provider ZIPCode | 326103003 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 40.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063473890 |
| Last Name Of The Provider | ALLEGRA |
| First Name Of The Provider | CARMEN |
| View All |
Similar Doctors
|
|
Dr. David N. Reisman, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. John R. Wingard, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Stephen P. Staal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James W. Lynch Jr., MD |
|
|
Dr. Jennifer M. Duff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nam H. Dang, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Merry J. Markham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Farrugia, MD
This Doctor is OpenDoctor Recommended.
|